Funding Daily Summary
Funding Daily Summary: What Happened on October 4, 2026
Ai3Bio emerges with $48 million Series A for immune-resetting therapies
The startup plans to test an antibody-guided mRNA approach, with initial human studies possible next year.
Today in brief
Ai3Bio disclosed a $48 million Series A to advance its immune-resetting therapy pipeline as it emerged from stealth.1
A targeted approach to immune reset
Founding investors Ziff Capital Partners and UPMC Enterprises led the round, with Cockrell Interests and Tanis Ventures also participating.1 Ai3Bio’s first intended target is overactive Th17 cells, which can contribute to autoimmune disease.1
The proposed therapy uses an antibody aimed at CD161 to direct an mRNA-carrying lipid nanoparticle to target cells and activate the cGAS-STING pathway.1 Scientific co-founder Jonathan Kagan said animal studies showed depletion of inflammatory T cells, including deep depletion in monkey spleens and lymph nodes.1
Kagan said the therapy’s durability has not been demonstrated in people.1 CEO Steven Altschuler said initial clinical studies could start with autoimmune liver diseases, and estimated the financing would last through the second quarter of 2027.1